Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preliminary efficacy of tocilizumab in COVID-19 patients (medical-record-based study)
ChiCTR2000033705Phase 4Completed
- Sponsor
- Xijing Hospital
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of tocilizumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Xijing Hospital. Primary endpoints: Clinical manifestations and Laboratory examination indicators. Started Jun 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000033705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033705.